系统综述:α1-抗胰蛋白酶缺乏症及其相关肝病的自然史
该系统综述通过检索多个数据库,纳入35项关于疾病进展和12项关于治疗的研究,分析α1-抗胰蛋白酶缺乏症(AATD)相关肝病的患病率和自然史,并评估肝移植结局。结果显示7%的儿童发生肝硬化,16.5%的儿童期个体需肝移植;存活至成人的个体中10.5%有肝硬化,14.7%需肝移植。肝移植是唯一有效治疗,5年生存率儿童超过90%、成人超过80%。
要点
- AATD相关肝病影响约10%的AATD个体,儿童中7%发生肝硬化。
- 儿童期16.5%需肝移植,成人期10.5%有肝硬化、14.7%需肝移植。
- 肝移植是唯一有效治疗,5年生存率儿童>90%、成人>80%。
核心结论
- AATD相关肝病的临床病程仍知之甚少,但影响约10%的AATD个体。
- 需要更多研究来早期识别有肝病风险的病人,并提供肝移植以外的替代治疗。
研究设计与样本
- 系统综述,在多个数据库中进行全面检索,由两名独立作者筛选文章并使用纽卡斯尔-渥太华量表评估偏倚。
- 共纳入35项与疾病进展相关的研究和12项与AATD治疗相关的研究,对可比结局进行数据合并分析。
主要发现
- 报告7%的儿童发生肝硬化,16.5%的儿童期个体需要肝移植。
- 存活至成人的个体中,10.5%有肝硬化,14.7%需要肝移植。
- 肝移植是报告的唯一有效治疗,结局优于其他适应证,5年生存率儿童超过90%、成人超过80%。
临床怎么用
- 原文未据此给出推荐。
局限性
- AATD相关肝病的临床病程仍知之甚少。
- 需要更多研究来早期识别有肝病风险的病人,并提供肝移植以外的替代治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is estimated to affect three million people worldwide. It causes liver disease in a proportion of carriers of the PiS and PiZ allele due to the formation and retention of polymers within the endoplasmic reticulum of hepatocytes. The reason for this selective penetrance is not known. Although clinical trials are underway, liver transplantation is the only effective treatment for liver disease due to AATD. AIMS: To report the prevalence and natural history of liver disease among individuals with AATD, and assess the outcomes of liver transplantation through systematic review. METHODS: A comprehensive search was conducted across multiple databases. Two independent authors selected the articles and assessed bias using the Newcastle-Ottawa Scale. Data were pooled for analysis, where comparable outcomes were reported. RESULTS: Thirty-five studies were identified related to disease progression and 12 for the treatment of AATD. Seven per cent of children were reported to develop liver cirrhosis, with 16.5% of individuals presenting in childhood requiring liver transplantation. Of those surviving to adulthood, 10.5% had liver cirrhosis and 14.7% required transplantation. Liver transplantation was the only effective treatment reported and outcomes compare favourably to other indications, with 5-year survival reported as over 90% in children and over 80% in adults. DISCUSSION: The clinical course of liver disease in individuals with AATD remains poorly understood, but affects about 10% of those with AATD. More research is required to identify those patients at risk of developing liver disease at an early stage, and to provide alternative treatments to liver transplantation.
引用
- Townsend SA, Edgar RG, Ellis PR, et al. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. Aliment Pharmacol Ther. 2018. PMID: 29446109. doi:10.1111/apt.14537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。